Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis
- 14 July 2021
- journal article
- research article
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 56 (11) , 2763-2770
Abstract
Haploidentical related donor transplantation (haplo-HCT) is associated with cytokine release syndrome (CRS). We conducted a multicenter retrospective study to analyze risk factors for CRS and outcomes after haplo-HCT. We included 451 patients from four academic centers receiving both peripheral blood and bone marrow grafts. Severe CRS was more common with PB vs. BM grafts (19.5% vs 4.9%, OR 2.9, p = 0.05). Multivariable analysis identified recipient CMV sero-positivity, prior transplant, HCT-CI score and donor–recipient sex mismatch as risk factors for severe CRS. Outcomes were analyzed with no CRS as the comparison group. Overall survival (OS) was superior with mild CRS (HR 0.64, p = 0.05) and worst with severe CRS (HR 2.12, p = 0.0038). Relapse risk was significantly decreased in both mild CRS (HR 0.38, p < 0.0001) and severe CRS (HR 0.17, p < 0.0001) groups. The risk of non-relapse mortality was notably higher in severe CRS group (HR 8.0, p < 0.0001), but not in mild CRS group. Acute GVHD was similar among groups. Chronic GVHD at 1 year was 18.5% for no CRS, 23% for mild CRS, and 4.3% for severe CRS (p = 0.0023), with the competing risk of early mortality and short follow up of surviving patients contributing to the low chronic GVHD rates in the severe CRS group.Keywords
This publication has 32 references indexed in Scilit:
- Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantationBlood, 2014
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor TransplantationJournal of Clinical Oncology, 2013
- Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow TransplantationSeminars in Oncology, 2012
- Into the Eye of the Cytokine StormMicrobiology and Molecular Biology Reviews, 2012
- Nonengraftment Haploidentical Cellular Immunotherapy for Refractory Malignancies: Tumor Responses without ChimerismTransplantation and Cellular Therapy, 2009
- HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation CyclophosphamideTransplantation and Cellular Therapy, 2008
- Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412New England Journal of Medicine, 2006
- Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCTBlood, 2005
- Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells.Journal of Clinical Investigation, 1996